Please click Additional Files below to see the full abstract

Andersen, Henrik

garwal, Kitty A

George, Monica

Khetan, Anurag

Langsdorf, Erik

MacIsaac, Glenn

Mcvey, Duncan

Onyskiw, Peter

Ou, May

Pendse, Girish

Rizzi, Giovanni

Tremml, Gabi

Wang, Chaojie

Xu, Ping

Xu, Sen

English

Engineering Conferences International

Poster Number 67 ENABLING PANDEMIC SPEED TO CLINIC FOR SARS-COV2 NEUTRALIZING ANTIBODIES   Peter Onyskiw, Bristol Myers Squibb peter.onyskiw@bms.com Ping Xu, Bristol Myers Squibb May Ou, Bristol Myers Squibb Monica George, Bristol Myers Squibb Chaojie Wang, Bristol Myers Squibb Giovanni Rizzi, , Bristol Myers Squibb Glenn MacIsaac, Bristol Myers Squibb Erik Langsdorf, Bristol Myers Squibb  Sen Xu, Bristol Myers Squibb Kitty Agarwal, Bristol Myers Squibb  Gabi Tremml, Bristol Myers Squibb Duncan Mcvey, Bristol Myers Squibb  Girish Pendse, Bristol Myers Squibb  Anurag Khetan, Bristol Myers Squibb Henrik Andersen, Bristol Myers Squibb   Key Words: SARS-CoV2, cell line development, upstream development, pandemic speed  SARS-CoV2 neutralizing monoclonal antibodies have been shown as an effective way to reduce the viral load of patients, minimizing risk of severe illness and hospitalization. BMS has undertaken a considerable effort for rapid commercialization of two such neutralizing antibodies, SARS-CoV2 C135 (Logavimab) and C144 (Crexavimab). Here we present an overview of the cell line and upstream process development efforts conducted at ‘pandemic speed’. These efforts along with several others were critical for enabling the IND submission within 6 months from DNA transfections, followed by a successful clinical supply campaign. Additionally, described are subsequent process developments efforts to further improve the robustness and productivity of the process.  

Enabling pandemic speed to clinic for SARS-CoV2 neutralizing antibodies

https://dc.engconfintl.org/cgi/viewcontent.cgi?filename=0&article=1114&context=ccexviii&type=additional

Enabling pandemic speed to clinic for SARS-CoV2 neutralizing antibodies

Abstract

Similar works

Full text

Available Versions

Engineering Conferences International